Pratik Desai, MD
Urology · Woodbridge, VANPI 1205822640
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (45.2%), travel and lodging and consulting fees — rather than concentrated in one kind of arrangement. 31 manufacturers reported payments, led by Procept Biorobotics Corporation at 50.2% of the total. Reporting peaked in 2022 at $5,362 and has fallen 67.7% since, to $1,732 in 2025.
Across 124 payments — averaging $102.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Procept Biorobotics Corporation$6K
- Histosonics, Inc.$631
- Sun Pharmaceutical Industries Inc.$615
- Intuitive Surgical$552
- Bioprotect Medical, Inc.$518
- Calyxo, Inc.$464
- plus $4K from 25 others
Across 1 payment — averaging $3193.99 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Spectrum Pharmaceuticals Inc.$3K
What the payments were for
- Consulting fees$3,28126%
- Speaking & faculty fees$1061%
- Travel & lodging$3,49227%
- Food & beverage$5,75245%
- Education$941%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Procept Biorobotics Corporation | 15 | $6,387 |
| Histosonics, Inc. | 2 | $631 |
| Sun Pharmaceutical Industries Inc. | 10 | $615 |
| Intuitive Surgical | 8 | $552 |
| Bioprotect Medical, Inc. | 7 | $518 |
| Calyxo, Inc. | 4 | $464 |
| Dendreon Pharmaceuticals LLC | 6 | $344 |
| Terumo Medical Corporation | 3 | $327 |
| Olympus America Inc. | 11 | $312 |
| Endo Pharmaceuticals Inc. | 4 | $305 |
| Boston Scientific | 3 | $218 |
| Angiodynamics, Inc. | 2 | $218 |
| Teleflex LLC | 3 | $202 |
| Ferring Pharmaceuticals Inc. | 3 | $190 |
| Asahi Intecc USA, Inc. | 1 | $164 |
| Astellas Pharma US Inc | 5 | $147 |
| Pfizer | 7 | $136 |
| Rochester Medical Corporation | 7 | $130 |
| Philips North America LLC | 1 | $116 |
| Urogen Pharma, Inc. | 3 | $114 |
| Amgen | 1 | $106 |
| Johnson & Johnson(2 entities) | 4 | $96 |
| Axonics, Inc. | 1 | $86 |
| C. R. Bard, Inc. & Subsidiaries | 2 | $71 |
| Palette Life Sciences, Inc. | 1 | $59 |
| Progenics Pharmaceuticals, Inc. | 2 | $49 |
| Tolmar Pharmaceuticals, Inc. | 3 | $47 |
| AbbVie(2 entities) | 2 | $44 |
| Neotract Inc. | 1 | $38 |
| Medtronic | 1 | $26 |
| Sanofi | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- AquaBeam Robotic System$5,830
- Da Vinci Surgical System$462
- CVAC Aspiration System$435
- BIOPROTECT BALLOON IMPLANT SYSTEM$271
- PROVENGE$266
- HydroPearl$197
- PERIPHERAL VASCULAR$164
- UroLift$143
- Nanoknife$133
- SpaceOAR VUE System - 10mL$128
- XIAFLEX$127
- AQUABEAM SYSTEM$124
- IGT D Peripheral$116
- XGEVA$106
- iTIND System$102
How this compares
$12,725 in reported general payments places this provider in the 80th percentile of 300 urology providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XtandiEnzalutamide | 294 | $4,094,856 |
| ErleadaApalutamide | 88 | $1,268,930 |
| OrgovyxRelugolix | 389 | $1,123,163 |
| Abiraterone Acetate | 136 | $172,715 |
| MyrbetriqMirabegron | 50 | $40,266 |
| Trospium Chloride | 75 | $6,128 |
| Tamsulosin Hcl | 306 | $4,313 |
| Methenamine Hippurate | 37 | $3,002 |
| Alfuzosin Hcl ErAlfuzosin Hcl | 124 | $2,246 |
| Trospium Chloride ErTrospium Chloride | 11 | $1,159 |
| Solifenacin Succinate | 21 | $761 |
| Tadalafil | 21 | $715 |
| Prednisone | 80 | $460 |
| Finasteride | 22 | $156 |
| Clotrimazole-BetamethasoneClotrimazole/Betamethasone Dip | 15 | $105 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncXtandi, Myrbetriq | $147 | $4,135,122344 claims |
| Johnson & JohnsonErleada | $96 | $1,268,93088 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 300 urology providers in Virginia.
Other urology in Woodbridge
- Nilay GandhiWoodbridge$138K
- Shawn MarhamatiWoodbridge$130K
- Inderjit SinghWoodbridge$14K
- Michael FabrizioVirginia Beach$1.5M
- Gregg EureVirginia Beach$1.4M
- Jessica DelongVirginia Beach$578K
- Robert GivenVirginia Beach$157K
- Michael WilliamsVirginia Beach$144K
- Patrick WhelanSuffolk$114K
- Jennifer Miles-ThomasVa Beach$101K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.